Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry.

tofacitinib - Generic mfg.

Jyseleca (filgotinib) - Gilead

Rinvoq (upadacitinib) - AbbVie

Olumiant (baricitinib) - Eli Lilly

Factors associated with the effectiveness and safety of Janus kinase inhibitors in rheumatoid arthritis: an 8-year observational study from the JAGUAR Registry. (PubMed, RMD Open) - Sep 1, 2026 - "In RA, chronic concomitant GC treatment and patient age are associated with JAK inhibitor discontinuation due to lack of effectiveness and ADRs, respectively."
Journal • Observational data • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

http://www.ncbi.nlm.nih.gov/pubmed/42674814

Beatriz Frade-Sosa; César Díaz-Torné; Cristina Martinez-Molina; Hèctor Corominas; Raimon Sanmartí

Sep 1, 2026